Formulation Development
SPI Pharma Expands Product Portfolio to Support Development, Manufacture & Administration of Oral Dosage Forms
SPI Pharma recently announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem…
Positive Update on the Development of New XF‐Platform Drug Formulations
Destiny Pharma recently announced the completion of the initial phase of its project with MedPharm to develop new topical formulations of the company’s novel XF‐platform…
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial
Rafael Pharmaceuticals, Inc. recently announced it has enrolled more than 75% of the 500 patients needed for its pivotal Phase 3 clinical trial for metastatic…
Origin Files Patent Application to Protect its Proposed Treatment for Viral & Bacterial Respiratory Infections
Origin, Inc. recently announced it has filed a provisional US patent application to enhance the ability of its plasma-generated nitric oxide (NO) antimicrobial and antiviral…
Immunogenesis Contracts ProBioGen for Development & Large-Scale Manufacturing Services
ProBioGen AG recently announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell…
Enlivex Announces Positive Final Safety & Efficacy Data From Clinical Trial
Enlivex Therapeutics Ltd. recently announced positive final safety and efficacy data from the company’s completed Phase 1b clinical trial in patients with severe sepsis. The…
Catalent Partners With Biohaven on New Fast-Dissolve Treatment
Catalent recently welcomed the announcement by Biohaven Pharmaceutical Holding Company Ltd. that the US FDA has approved its NURTEC ODT (rimegepant) for the acute treatment…
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials
Arcutis Biotherapeutics, Inc. recently announced that, at the request of the US FDA, it has submitted a protocol amendment to the FDA to include children…
CERo Therapeutics Announces Research Collaboration With Lyell Immunopharma; Completion of Financing
Under the terms of the agreement, CERo and Lyell will collaborate to pursue proof-of-concept studies for a new class of cell-based therapeutics directed against….
Evonik Achieves Major Biotech Breakthrough With a New Animal-Free & Fermentation-Based Collagen Platform
Evonik recently announced the development of an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials…..
Tyligand Bioscience & Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
Tyligand Bioscience and Context Therapeutics LLC recently announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of….
Nurix Therapeutics Closes $120-Million Financing to Advance Targeted Protein Modulation Drug Pipeline
With the funds raised in this financing, Nurix is well positioned to bring its targeted protein modulation therapeutics into the clinic…..
Zydus & XOMA Announce Exclusive Licensing Agreement
Zydus Cadila and XOMA Corporation recently announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that….
DEINOVE Passes Second Milestone of the AGIR Program
DEINOVE recently announced it has successfully completed the second key milestone of the AGIR program – Antibiotics against Resistant Infectious Germs – which is supported by……
Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board
Ajinomoto Bio-Pharma Services recently announced the formation of its External Advisory Board (EAB) to provide insight into industry trends and…..
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections, Including COVID-19
BeyondSpring Inc. recently announced the submission of a provisional US patent application for its pipeline asset BPI-002, for methods of treating viral infections, including COVID-19,…
Menlo Therapeutics & Foamix Pharmaceuticals Complete Merger
Menlo Therapeutics Inc. recently announced the completion of its merger with Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger…
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 Study
Retrophin, Inc. recently announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of…
10 Drugs in Pre-Registration Phase Have Potential to Reach Blockbuster Status by 2025
Out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, 10 have the potential to reach…
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment & Prevention of Coronavirus Disease
Emergent BioSolutions Inc. recently announced it has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19). These product candidates…